ReviewCell adhesion & migration
Glioma angiogenesis: Towards novel RNA therapeutics.
Review in Cell adhesion & migration. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- SYHA1813, A VEGFR and CSF1R Inhibitor, in Patients With Recurrent High-Grade Gliomas: A Multicenter, Open-Label Phase I Study.Annals of clinical and translational neurology · 2025Article
- Unveiling the therapeutic promise of EphA2 in glioblastoma: a comprehensive review.Discover oncology · 2024Review
- Single-cell signatures identify microenvironment factors in tumors associated with patient outcomes.Cell reports methods · 2024Article
- Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood-brain barrier and exhibits potent activity against glioblastoma.Acta pharmaceutica Sinica. B · 2023Article
- In vivo antiangiogenic effect of nimbolide, trans-chalcone and piperine for use against glioblastoma.BMC cancer · 2023Article
- The Significant Role of microRNAs in Gliomas Angiogenesis: A Particular Focus on Molecular Mechanisms and Opportunities for Clinical Application.Cellular and molecular neurobiology · 2023Review
- The road-map for establishment of a prognostic molecular marker panel in glioma using liquid biopsy: current status and future directions.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COVID-19 pandemic.Advanced drug delivery reviews · 2022Review
- Pro- and Antiangiogenic Factors in Gliomas: Implications for Novel Therapeutic Possibilities.International journal of molecular sciences · 2021Review
- Insights into Multifunctional Nanoparticle-Based Drug Delivery Systems for Glioblastoma Treatment.Molecules (Basel, Switzerland) · 2021Review
- A radiomics-based comparative study on arterial spin labeling and dynamic susceptibility contrast perfusion-weighted imaging in gliomas.Scientific reports · 2020Article
- Relationship between expression of XRCC1 and tumor proliferation, migration, invasion, and angiogenesis in glioma.Investigational new drugs · 2019Article
- Roles of EphA2 Receptor in Angiogenesis Signaling Pathway of Glioblastoma Multiforme.The Malaysian journal of medical sciences : MJMS · 2018Review
- miRNAs: micro-managers of anticancer combination therapies.Angiogenesis · 2017Review
- MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics.Cancer medicine · 2016Review
- Current progress for the use of miRNAs in glioblastoma treatment.Molecular neurobiology · 2013Review
- Which drug or drug delivery system can change clinical practice for brain tumor therapy?Neuro-oncology · 2013Review
- MiR-15b and miR-152 reduce glioma cell invasion and angiogenesis via NRP-2 and MMP-3.Cancer letters · 2013Article
- Article
- Down-regulation of miR-101 in endothelial cells promotes blood vessel formation through reduced repression of EZH2.PloS one · 2011Article
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain tumors exhibit marked and aberrant blood vessel formation indicating angiogenic endothelial cells as a potential target for brain tumor treatment. The brain tumor blood vessels are used for nutrient delivery, and possibly for cancer cell migration. The process of angiogenesis is complex and involves multiple players. The current angiogenesis inhibitors used in clinical trials mostly target single angiogenic proteins and so far show limited effects on tumor growth. Besides the conventional angiogenesis inhibitors, RNA-based inhibitors such as small-interfering RNAs (siRNAs) are being analyzed for their capacity to silence the message of proteins involved in neovascularization. More recently, a new family of non-coding RNAs, named angiomirs [microRNAs (miRNAs) involved in angiogenesis] has emerged. These small RNAs have the advantage over siRNAs in that they have the potential of silencing multiple messages at the same time and therefore they might become therapeutically relevant in a "one-hit multiple-target" context against brain tumor angiogenesis. In this review we will discuss the emerging technologies in anti-angiogenesis emphasizing on RNA-based therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.